Based on durable response data, TAR-200 has been given priority review for the treatment of patients with high-risk ...

Panelists discuss how managing amivantamab-related adverse events such as leg edema requires understanding of underlying ...

Panelists discuss how the COCOON study’s advanced dermatologic prophylaxis protocol, including systemic antibiotics and ...

Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the ...

Each component of an antibody-drug conjugates—payload, linker, and antibody—play a unique role in building the treatment’s use and safety profile.

Panelists discuss the growing promise of GPRC5D-targeted therapy in relapsed/refractory multiple myeloma, highlighting MonumenTAL-1 trial data showing encouraging responses in heavily pretreated ...

Panelists discuss the evolving role of bispecific antibodies in relapsed/refractory multiple myeloma, emphasizing their value as off-the-shelf options for patients post chimeric antigen receptor ...

If patients with breast cancer hyperglycemia or symptoms of it at home, a short break from capivasertib may be required, according to Hope Rugo, MD.

Most patients demonstrated at least partial response to tarlatamab in a real-world population with extensive-stage small cell ...

Erika Hamilton is the director of breast and gynecologic cancer research at Sarah Cannon Research Institute in Nashville, Tennessee.

New therapies in breast cancer, particularly ADCs, present unique safety profiles for nurses to be aware of, according to Erika Hamilton, MD.

Data from a research database link ctDNA positivity in early breast cancer with poorer survival and higher recurrence risk.